Granted Patent
B2
US 12,274,684 · App. 18/535,865 · Granted Apr 15, 2025
Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
Inventors:
Roger Jeffs (Chapel Hill, NC); Thomas Petersen (Durham, NC); Roger M. Ilagan (Burlington, NC); Michael Wade (Chapel Hill, NC)
Assignee:
United Therapeutics Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
Claims (14)
1. A method of preparing a pharmaceutical product a mesenchymal stem cell (MSC) or a part of a culture medium that has been in contact with the MSC and contains one or more components of the MSC, comprising contacting a culture comprising an MSC with a prostacyclin and thereafter isolating the MSC or a part of a culture medium that has been in contact with the MSC and contains one or more components of the MSC.
2. The method of claim 1 , wherein the component(s) of the MSC is selected from the group consisting of an exosome, a microvesicle, a microRNA, a messenger RNA, a non-coding RNA, a mitochondria, a growth factor, and combinations thereof.
3. The method of claim 1 , wherein the pharmaceutical product further comprises an endothelial progenitor cell (EPC).
4. The method of claim 3 , wherein the EPC is obtained from a subject who is to be treated with the pharmaceutical product.
5. The method of claim 4 , wherein the EPC is transformed with a nucleic acid that increases the expression of biological activity of a protein selected from the group consisting of endothelial nitric oxide synthase (eNOS), heme oxygenase (HMOX1) and prostacyclin synthase (PTGIS).
6. The method of claim 5 , wherein the nucleic acid encodes the protein.
7. The method of claim 1 , wherein the prostacyclin is selected from the group consisting of epoprostenol, treprostinil, beraprost, ilprost, a PGI 2 receptor agonist, and pharmaceutically acceptable salts thereof.
8. The method of claim 7 , wherein the prostacyclin is treprostinil or a pharmaceutically acceptable salt or ester thereof.
9. The method of claim 1 , wherein the MSC is a mesenchymal precursor cell (MPC).
10. The method of claim 1 , wherein the MSC is obtained from bone marrow.
11. The method of claim 1 , wherein contacting with the prostacyclin comprises adding the prostacyclin to the MSC culture at a concentration from about 200 μg/mL to about 300 μg/mL.
12. The method of claim 1 , wherein the contacting with the prostacyclin occurs for at least 24 hours.
13. The method of claim 11 , wherein the contacting with the prostacyclin occurs for at least 24 hours.
14. The method of claim 13 , wherein the prostacyclin is treprostinil.
Continuity (5)
Provisional Application
61750458
· Jan 9, 2013
References Cited (147)
US 3089815A
· Lieb et al.
· 1963
[cited by applicant]
US 4352883A
· Lim
· 1982
[cited by applicant]
US 4353888A
· Sefton
· 1982
[cited by applicant]
US 4714680A
· Civin
· 1987
[cited by applicant]
US 4965204A
· Civin
· 1990
[cited by applicant]
US 4968733A
· Muller et al.
· 1990
[cited by applicant]
US 4976859A
· Wechs
· 1990
[cited by applicant]
US 4983393A
· Cohen et al.
· 1991
[cited by applicant]
US 5026365A
· Rossini et al.
· 1991
[cited by applicant]
US 5035994A
· Civin
· 1991
[cited by applicant]
US 5071741A
· Brockbank
· 1991
[cited by applicant]
US 5084350A
· Chang et al.
· 1992
[cited by applicant]
US 5130144A
· Civin
· 1992
[cited by applicant]
US 5137809A
· Loken et al.
· 1992
[cited by applicant]
US 5158881A
· Aebischer et al.
· 1992
[cited by applicant]
US 5284761A
· Aebischer et al.
· 1994
[cited by applicant]
US 5643192A
· Hirsh et al.
· 1997
[cited by applicant]
US 5651982A
· Marx
· 1997
[cited by applicant]
US 5691176A
· Lebkowski et al.
· 1997
[cited by applicant]
US 5693531A
· Chiorini et al.
· 1997
[cited by applicant]
US 5750397A
· Tsukamoto et al.
· 1998
[cited by applicant]
US 5800828A
· Dionne et al.
· 1998
[cited by applicant]
US 5811094A
· Caplan et al.
· 1998
[cited by applicant]
US 6387369B1
· Pittenger et al.
· 2002
[cited by applicant]
US 6468527B2
· Austin et al.
· 2002
[cited by applicant]
US 7638128B2
· Dzau et al.
· 2009
[cited by applicant]
US 20030118567A1
· Stewart
· 2003
[cited by applicant]
US 20070065414A1
· Freyman et al.
· 2007
[cited by applicant]
US 20090274665A1
· Akabutu et al.
· 2009
[cited by applicant]
US 20100040584A1
· Melero-Martin et al.
· 2010
[cited by applicant]
US 20110003008A1
· Lim
· 2011
[cited by applicant]
WO WO9204033A1
· 1992
[cited by applicant]
WO WO9219195A1
· 1992
[cited by applicant]
WO WO9314191A1
· 1993
[cited by applicant]
WO WO9429438A1
· 1994
[cited by applicant]
WO WO9505452A1
· 1995
[cited by applicant]
WO WO9507611A1
· 1995
[cited by applicant]
WO WO9527071A1
· 1995
[cited by applicant]
WO WO9627287A1
· 1996
[cited by applicant]
WO WO9629862A1
· 1996
[cited by applicant]
WO WO9721824A1
· 1997
[cited by applicant]
WO WO9721825A1
· 1997
[cited by applicant]
WO WO9814058A1
· 1998
[cited by applicant]
WO WO9820027A2
· 1998
[cited by applicant]
WO WO0024897A1
· 2000
[cited by applicant]
WO WO0104268A1
· 2001
[cited by applicant]
WO WO2004050180A2
· 2004
[cited by applicant]
WO WO2004084921A1
· 2004
[cited by applicant]
WO WO2004085630A1
· 2004
[cited by applicant]
WO WO2006032092A1
· 2006
[cited by applicant]
WO WO2009057313A1
· 2009
[cited by applicant]
WO WO2009105044A1
· 2009
[cited by applicant]
WO WO2012027740A1
· 2012
[cited by applicant]
WO WO2014022373A1
· 2014
[cited by applicant]
WO WO2014022376A2
· 2014
[cited by applicant]
“Second European Consensus Document on Chronic Critical Leg Ischemia”, Circulation, Nov. 1991, 84(4 Suppl.):IV-1-IV-26.
[cited by applicant]
Abisambra et al., “Abstracts for the 19th Annual Meeting of the American Society for Neural Therapy and Repair,” Cell Transplantation, 2012, 21, pp. 773-797.
[cited by applicant]
Actelion Pharmaceuticals, “VELETRI: epoprostenol,” (2011); col. 1, para 5; col. 2, para 2.
[cited by applicant]
Aizman et al., “Extracellular Matrix Produced by Bone Marrow Stromal Cells and by Their Derivative, SB623 Cells. Supports Neural Cell Growth,” Journal of Neuroscience Research, 2009, 87, pp. 3198-3206.
[cited by applicant]
Allen et al., “Type I collagen, fibrin and PuraMatrix matrices provide permissive environments for human endothelial and mesenchymal progenitor cells to form neovascular networks,” Journal of Tissue Engineering and Rege…
[cited by applicant]
Asahara et al., “Isolation of Putative Progenitor Endothelial Cells for Angiogenesis,” Science, Feb. 14, 1997, vol. 275, pp. 964-967.
[cited by applicant]
Assmus et al., “Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI),” Circulation, Nov. 11, 2002, 106, pp. 3009-3017.
[cited by applicant]
Barst, Robyn MD, FACC, “Is it Possible to Reverse the Endothelial Dysfunction in Pulmonary Arterial Hypertension?,” Journal of the American College of Cardiology, 2007, 49(14), pp. 1572-1574.
[cited by applicant]
Boeing et al., “Single-step isolation of extracellular vesicles by size-exclusion chromatography,” Journal of Extracellular Vesicles, Sep. 8, 2014, 3:1:23430.
[cited by applicant]
Bregni et al., “Human Peripheral Blood Hematopoietic Progenitors Are Optimal Targets of Retroviral-Mediated Gene Transfer,” Blood, Sep. 15, 1992, 80(6), pp. 1418-1422.
[cited by applicant]
Chen et al., “Effect on Left Ventricular Function of Intracoronary Transplantation of Autologous Bone Marrow Mesenchymal Stem Cell in Patients With Acute Myocardial Infarction,” American Journal Cardiology, Jul. 2004, v…
[cited by applicant]
Clinical All-Round, Nov. 2009, 58(11):2324-2337, with English-language translation of relevant part.
[cited by applicant]
Coffin et al., “Development and Applications of Retroviral Vectors,” Eds. Retroviruses, Cold Springs Harbor Laboratory Press, 1997, Chapter 9, pp. 437-473.
[cited by applicant]
D'Alonzo et al., “Survival in Patients with Primary Pulmonary Hypertension,” Ann. Intern. Med., Sep. 1, 1991, 115(5), pp. 343-349.
[cited by applicant]
Das et al., “The Role of Hypoxia in Bone Marrow-Derived Mesenchymal Stem Cells: Considerations for Regenerative Medicine Approaches,” Tissue Engineering: Part B, Apr. 1, 2010, 16(2), pp. 159-168.
[cited by applicant]
Di Stefano et al., “The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia,” Thrombosis and Haemostasis, Oct. 13, 2008, 100(5), pp. 871-877.
[cited by applicant]
Dominici et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society of Cellular Therapy position statement,” Cytotherapy, 2006, 8(4), pp. 315-317.
[cited by applicant]
Dormany et al., “Chronic Critical limb Ischemia,” J. Vase. Surg. 2000, 31, pp. S168-S175.
[cited by applicant]
Doyle et al., “Endothelial Progenitor Cells,” Endothelium, 2006, 13, pp. 403-410.
[cited by applicant]
Eells et al., “Advances in Prostacyclin Therapy for Pulmonary Arterial Hypertension,” Critical Care Nurse, Apr. 2004, 24(2), pp. 42-54.
[cited by applicant]
Eneroth et al., “Amputation for occlusive arterial disease, A prospective multicentre study of 177 amputees,” Int. Orthop. (SICOT), 1992, 16, pp. 383-387.
[cited by applicant]
Flamme et al., “Induction of vasculogenesis and hematopoiesis in vitro,” Development, 1992, 116(2), pp. 435-439.
[cited by applicant]
Grant et al., “Iloprost: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Peripheral Vascular Disease, Myocardial Ischaemia and Extracorporeal Circulation Procedures,” Drugs, …
[cited by applicant]
Groth et al., “Inflammatory cytokines in pulmonary hypertension,” Respiratory Research, 2014, 15:47, 10 pages.
[cited by applicant]
Gruber, Scott A., “The Case for Local Immunosuppression,” Transplantation, Jul. 1992, 54, pp. 1-11.
[cited by applicant]
Hall et al., “Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment”, European Respiratory Journal, vol. 38, No. 4, Mar. 15, 2011 (Mar. 15, 2011), pp…
[cited by applicant]
Hatzopoulos et al., “Isolation and characterization of endothelial progenitor cells from mouse embryos,” Development, 1998, 125(8), pp. 1457-1468.
[cited by applicant]
He et al., “Angiogenic Function of Prostacyclin Biosynthesis in Human Endothelial Progenitor Cells,” Circulation Research, Jul. 3, 2008, vol. 103, No. 1, pp. 80-88.
[cited by applicant]
Hill et al, “Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk,” N. Engl. J. Med., 2003, 348, pp. 593-600.
[cited by applicant]
Hoogduijn et al., “The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy,” International Immunopharmacology, 2010, 10, pp. 1496-1500.
[cited by applicant]
Hu et al., “Exosomal miRNAs: biological properties and therapeutic potential,” Frontiers in Genetics, Apr. 20, 2012, 3(56), pp. 1-9.
[cited by applicant]
Humbert et al., “Cellular and Molecular Pathobiology of Pulmonary Arterial Hypertension,” J. Am. Coll. Cardiol., 2004, 43(12:SuppIS), pp. 13S-24S.
[cited by applicant]
Ingram et al., “Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood,” Blood, Jun. 29, 2004, 104, pp. 2752-2760.
[cited by applicant]
Ishii et al., “Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia,” Atherosclerosis, (2009) vol. 206, pp. 109-118.
[cited by applicant]
Isner et al., “Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization,” J. Clin. Invest., May 1999, 103(9), pp. 1231-1236.
[cited by applicant]
Kalka et al., “Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization,” P.N.A.S., Mar. 29, 2000, 97(7), pp. 3422-3427.
[cited by applicant]
Kamio et al., “Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture,” Am. J. Physiol. Lung Cell. Mol. Physiol., 2008, 294, pp. L1226-L1232.
[cited by applicant]
Kamio et al., “Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture”, Am J Physiol Lung Cell Mol Physiol, vol. 294, pp. L1226-L1232 (2008).
[cited by applicant]
Karlsson et al., “Nucleation and Growth of Ice Crystals Inside Cultured Hepatocytes During Freezing in the Presence of Dimethyl Sulfoxide,” Biophysical J., Dec. 1993, 65, pp. 2524-2536.
[cited by applicant]
Kawabe et al., “Role of Autocrine Prostacyclin System in Crucial Functions of Endothelial Progenitor Cells,” Circ. J., 2008, 72 (Suppl. 1):503, PE-570.
[cited by applicant]
Kawabe, “Q&A about Thrombosis (Part 6): Please explain prostacyclin and revascularization,” Thrombosis and Circulation, 2011, 19(1):189-191.
[cited by applicant]
Keeley et al., “Fibrocytes: Bringing new insights into mechanisms of inflammation and fibrosis,” Int. J. Biochem. Cell Biol., 2010, 42, pp. 535-542.
[cited by applicant]
Keily et al., “Pulmonary hypertension: diagnosis and management,” BMJ, 2013, 346:f2028, 1-12.
[cited by applicant]
Kuo et al., “Effect of Prostaglandin 12 Analogs on Cytokine Expression in Human Myeloid Dendritic Cells via Epigenetic Regulation,” Molecular Medicine, 2012, 18, pp. 433-444.
[cited by applicant]
Lai et al., “Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury,” Stem Cell Research, 2010, 4(3):214-222.
[cited by applicant]
Lai et al., “Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease,” Regen. Med., 2011, 6(4):481-492.
[cited by applicant]
Lau et al., “Stem Cells and Regenerative Medicine in Lung Biology and Diseases,” Molecular Therapy, GB, (Mar. 6, 2012), Jun. 2012, vol. 20, No. 6, pp. 1116-1130.
[cited by applicant]
Lee et al., “Exosomes Mediate the Cytoprotective A-ction of Mesenchymal Stromal Cells on Hypoxia-Induced Pulmonary Hypertension,” Circulation, Oct. 31, 2012, 126(22), pp. 2601-2611.
[cited by applicant]
Liu et al., “Engineered Endothelial Progenitor Cells That Overexpress Prostacyclin Protect Vascular Cells,” Journal of Cellular Physiology, Mar. 20, 2012, 227(7), pp. 2907-2916.
[cited by applicant]
Mayer et al., “Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: Autocrine and paracrine role on osteoblastic and endothelial differentiation,” Journal of Cellular Biochemistry, vol…
[cited by applicant]
Murohara et al., “Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization,” J. Clin. Invest, Jun. 2000, 105(11), pp. 1527-1536.
[cited by applicant]
Nagaya et al., “Hybrid Cell-Gene Therapy for Pulmonary Hypertension Based on Phagocytosing Action of Endothelial Progenitor Cells,” Circulation, Jun. 30, 2003, 108, pp. 889-895.
[cited by applicant]
Ribatti, Domenico, “The discovery of endothelial progenitor cells, An historical review,” Leukemia Research, 2007, 31, pp. 439-444.
[cited by applicant]
Risau et al., “Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies,” Development, 1988, 102, pp. 471-478.
[cited by applicant]
Risau, Werner, “Differentiation of endothelium,” FASEB J., 1995, 9(10), pp. 926-933.
[cited by applicant]
Risau, Werner, “Mechanisms of angiogenesis,” Nature, Apr. 17, 1997, 386, pp. 671-674.
[cited by applicant]
Rissanen et al., “Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb—on the way to the clinic,” European Journal of Clinical Investigation, 2001, 31, pp. 651-666.
[cited by applicant]
Ruan et al., “Prostacyclin therapy for pulmonary arterial hypertension,” Texas Heart Institute Journal (2010) vol. 37, No. 4, pp. 391-399.
[cited by applicant]
Sahara, Makoto, Clinic All-Round, 2009, 58(11), pp. 2324-2336, with English translation of indicated relevant portions.
[cited by applicant]
Shantsila et al., “Endothelial Progenitor Cells in Cardiovascular Disorders,” Journal of the American College of Cardiology vol. 49 (2007) p. 741-752; abstract; p. 745, col. 2 para 2-3.
[cited by applicant]
Shintani, Satoshi, Heart View, 2011, 15(8): pp. 90-96, with English translation of indicated relevant portions.
[cited by applicant]
Smadja et al., “Treprostinil increases the No. and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension,” Angiogenesis, 2011, 14(1), pp. 17-27.
[cited by applicant]
Smithies et al., “Insertion of DNA sequences into the human chromosomal Beta-globin locus by homologous recombination,” Nature, Sep. 19, 1985, 317, pp. 230-234.
[cited by applicant]
Takahashi et al., “Ischemia and cytokine induce-dmobilization of bone marrow derived endothelial progenitor cells for neovascularization,” Nature Medicine, Apr. 1999, 5(4), pp. 434-438.
[cited by applicant]
Thery et al., “Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids,” Current Protocols in Cell Biol., 2006, 3.22.1-3.22.29.
[cited by applicant]
Topol et al., “Combined Tissue-Type Plasminogen Activator and Prostacyclin Therapy for Acute Myocardial Infarction,” J Am Coll Cardiol, 1989, 14(4), pp. 877-884.
[cited by applicant]
Tyrrell et al., “Critical leg ischaemia: an appraisal of clinical definitions,” Br. J. Surg., Feb. 1993, 80, pp. 177-180.
[cited by applicant]
Umar et al., “Novel Approaches to Treat Experimental Pulmonary Arterial Hypertension: A Review,” Journal of Biomedicine and Biotechnology, vol. 2010, pp. 1-11.
[cited by applicant]
Wang et al., “Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension,” J. Am. Coll. Cardiol., 2007, 49(14), pp. 1566-1571.
[cited by applicant]
Williams et al., “Mesenchymal Stem Cells: Biology, Pathophysiology, Translational Findings, and Therapeutic Implications for Cardiac Disease,” Circ Res. 2011;109:923-940; abstract; p. 925, col. 2, para 4.
[cited by applicant]
Yoder et al., “Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals,” Blood, 2007, 109, pp. 1801-1809.
[cited by applicant]
Zhao et al., “Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow-Derived Endothelial-Like Progenitor Cells,” Circ. Res., 2006, 96, pp. 442-450.
[cited by applicant]
Zhen et al., “Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells,” Cytotherapy, Sep. 1, 2010, 12(5…
[cited by applicant]
Zheng et al., “Fidelity of targeted recombination in human fibroblasts and murine embryonic stem cells,” Proc. Natl. Acad. Sci. USA, Sep. 1991, 88, pp. 8067-8071.
[cited by applicant]